Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 1 to 25 of 903

TitleReference numberPublishedLast updated
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Givinostat for treating Duchenne muscular dystrophy in people 6 years and overTA1157
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyTA1156
Rozanolixizumab for treating antibody-positive generalised myasthenia gravisTA1155
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesityTA1152
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentTA1153
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)TA1154
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancerTA1150
Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)TA1151
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelomaTA1149
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and overTA1147
Sodium zirconium cyclosilicate for treating hyperkalaemiaTA1148
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitorsTA1146
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinomaTA1145
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)TA1144
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopauseTA1143
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsTA1142
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1140
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)TA1141
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatmentTA1139
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerTA1138
Molnupiravir for treating COVID-19TA1056
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19TA878
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerTA1136
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1137

Results per page

  1. 10
  2. 25
  3. 50
  4. All